Stock Track | REMEGEN Plummets 5.19% Intraday as Profit-Taking Follows Fully Priced-In Catalysts

Stock Track04-23

REMEGEN's stock plummeted 5.19% intraday, extending a high-level correction as recent positive developments appear to have been fully absorbed by the market.

The decline follows significant catalysts, including a $650 million upfront payment from AbbVie under an exclusive licensing agreement for the bispecific antibody drug RC148 and the presentation of core data from its novel PR-ADC payload recovery platform at a major medical conference. However, with the A-share counterpart having surged substantially in the prior week and southbound capital persistently reducing holdings, traders are engaging in profit-taking.

The movement reflects a market view that prior gains were substantial and multiple positive catalysts have now been fully digested, leading to a technical pullback from recent highs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147793946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 09:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147793946","market":"sg","top_or_hot":-1,"title":"Stock Track | REMEGEN Plummets 5.19% Intraday as Profit-Taking Follows Fully Priced-In Catalysts","media":"Stock Track","content":"<p>REMEGEN's stock plummeted 5.19% intraday, extending a high-level correction as recent positive developments appear to have been fully absorbed by the market.</p><p>The decline follows significant catalysts, including a $650 million upfront payment from AbbVie under an exclusive licensing agreement for the bispecific antibody drug RC148 and the presentation of core data from its novel PR-ADC payload recovery platform at a major medical conference. However, with the A-share counterpart having surged substantially in the prior week and southbound capital persistently reducing holdings, traders are engaging in profit-taking.</p><p>The movement reflects a market view that prior gains were substantial and multiple positive catalysts have now been fully digested, leading to a technical pullback from recent highs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Plummets 5.19% Intraday as Profit-Taking Follows Fully Priced-In Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Plummets 5.19% Intraday as Profit-Taking Follows Fully Priced-In Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-23 09:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN's stock plummeted 5.19% intraday, extending a high-level correction as recent positive developments appear to have been fully absorbed by the market.</p><p>The decline follows significant catalysts, including a $650 million upfront payment from AbbVie under an exclusive licensing agreement for the bispecific antibody drug RC148 and the presentation of core data from its novel PR-ADC payload recovery platform at a major medical conference. However, with the A-share counterpart having surged substantially in the prior week and southbound capital persistently reducing holdings, traders are engaging in profit-taking.</p><p>The movement reflects a market view that prior gains were substantial and multiple positive catalysts have now been fully digested, leading to a technical pullback from recent highs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1147793946","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147793946","pubTimestamp":1776908718,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN's stock plummeted 5.19% intraday, extending a high-level correction as recent positive developments appear to have been fully absorbed by the market.The decline follows significant catalysts,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|REMEGEN盘中暴跌5.19%，获利了结跟随完全定价的催化剂","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN's stock plummeted 5.19% intraday, extending a high-level correction as recent positive developments appear to have been fully absorbed by the market.The decline follows significant catalysts, including a $650 million upfront payment from AbbVie under an exclusive licensing agreement for the bispecific antibody drug RC148 and the presentation of core data from its novel PR-ADC payload recovery platform at a major medical conference. However, with the A-share counterpart having surged substantially in the prior week and southbound capital persistently reducing holdings, traders are engaging in profit-taking.The movement reflects a market view that prior gains were substantial and multiple positive catalysts have now been fully digested, leading to a technical pullback from recent highs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147793946","isCrawlerRequest":true}